A Study of RC48-ADC for the Treatment of Locally Advanced or Metastatic Breast Cancer With Low Expression of HER2

NCT04400695 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

366

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: RC48-ADC
DRUG: Paclitaxel Injection
DRUG: Docetaxel Injection
DRUG: Vinorelbine Tartrate Injection
DRUG: Capecitabine Tablets

Sponsor

RemeGen Co., Ltd.